Challenging Cases in Breast Cancer: Rare Breast Cancer Histologies and Presentations
This activity includes a panel of experts from breast radiation oncology, surgical oncology, medical oncology, and pathology to discuss the following rare histologies/breast cancer presentations: 1) Pleomorphic LCIS- diagnosis and differential (path) appropriate margin width (surgeon), role of adjuvant radiation (rad onc), role for endocrine therapy (med onc) 2) Phyllodes tumor- diagnosis and differential (path), surgical management (surg onc), adjuvant RT (rad onc) - discuss NRG trial on Phyllodes as part of the panel 3) Male breast cancer- mastectomy vs. breast conservation (surgery), use of genomic scores like oncotype, tamoxifen vs. AI, (med onc), role of adjuvant radiation and how it differs from women (rad onc) 4. Metaplastic breast cancer: mastectomy vs. breast conservation and optimal margin width (surg onc), systemic therapy, endocrine therapy and more targeted agents (med onc), adjuvant RT (rad onc).
- Welcome and Introduction to the Panel; Case 1 Presentation
Naamit Kurshan Gerber, MD - Introduction
Jorge Reis-Filho, MD, PhD - Case 1 presentation
Kandace P. McGuire, MD - Summary and discussion of Case 1
Jose Pablo Leone, MD - Closing comments on Case 1
- Case 2
Naamit Kurshan Gerber, MD - Introduction of Case 2
Jorge Reis-Filho, MD, PhD - Case 2 presentation
Kandace P. McGuire, MD and Wendy A. Woodward, MD, PhD, FASTRO - Summary, Discussion and Q&A for Case 2
- Case 3 - Phyllodes Tumors
Naamit Kurshan Gerber, MD - Introduction of Case 3
Kandace P. McGuire, MD and Kiri Cook, MD - Case 3 presentation
Jose Pablo Leone, MD and Wendy A. Woodward, MD, PhD, FASTRO - Comments on Case 3
- Case 4 - Male Breast Cancer
Naamit Kurshan Gerber, MD - Introduction of Case 4
Jose Pablo Leone, MD and Kiri Cook, MD - Case 4 presentation
Full Panel - Discussion and Q&A for Case 4
This activity is available from September 12, 2023, through 11:59 p.m. Eastern time on September 11, 2025.
This activity was originally recorded at the 2022 ASTRO Annual Meeting.
The activity is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, nurses, pathologists and residents.
Upon completion of this activity, participants should be able to:
- Have a better sense of the literature that exists (and does not exist) with regard to these rarer entities.
- Better manage these rare histologies with input from experts in the field.
Naamit Kurshan Gerber, MD, is employed by NYU Langone Health, Department of Radiation Oncology.
Jorge Reis-Filho, MD, PhD, is employed by Memorial Sloan Kettering Cancer Center. Dr. Reis-Filho receives compensation from Paige.AI, Repare Therapeutics, Eli Lilly and Personalis. Dr. Reis-Filho also receives honoraria from Volition RX. Dr. Reis-Filho maintains stock options and shares in Grupo Oncoclinicas and Paige.AI. He is a member of the Board of Directors for Grupo Oncoclinicas.
Wendy A. Woodward, MD, PhD, FASTRO, is employed by The University of Texas MD Anderson Cancer Center. Dr. Woodward receives compensation and serves on the speaker’s bureau of Genomic Health, Inc. Dr. Woodward also serves on the Advisory Board of Epic Sciences. Dr. Woodward serves as a Steering Committee Member on the ASTRO Science Council.
Kandace P. McGuire, MD, is employed by Virginia Commonwealth University Health System. Dr. McGuire serves on the Strategic Advisory Board of Mammotome, Inc.
Jose Pablo Leone, MD, is employed by the Dana-Farber Cancer Institute. Dr. Leone receives research funding from Kazia Therapeutics and compensation from Minerva Biotechnologies.
Kiri Cook, MD, is employed by Oregon Health and Science University.
The person(s) above served as the developer(s) of this activity. Additionally, the Education Committee had control over the content of this activity. All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the member rate.
Student/Grad Student/PGY: $49
Postdoctoral Fellow: $49
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website until September 11, 2025, regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.